Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study
Author:
Affiliation:
1. Department of Breast Medical Oncology Zhejiang Cancer Hospital Hangzhou China
2. The Medical Department 3D Medicines Inc Shanghai China
3. Department of Oncology The First Affiliated Hospital of Nanjing Medical University Nanjing China
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2460
Reference35 articles.
1. Novel Precision Medicine Trial Designs
2. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
3. Attitudes toward molecular testing for personalized cancer therapy
4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
5. Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfilER Study.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. CDCA3 promotes the proliferation and migration of hypopharyngeal squamous cell carcinoma cells by activating the Akt/mTOR pathway;Biotechnology and Genetic Engineering Reviews;2023-03-09
2. Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China;Breast Cancer Research and Treatment;2021-09-01
3. A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos;Frontiers in Pharmacology;2021-04-12
4. Transcriptome Profiling and Cytological Assessments for Identifying Regulatory Pathways Associated With Diorcinol N-Induced Autophagy in A3 Cells;Frontiers in Pharmacology;2020-10-15
5. Identification of PIK3CA aberrations associated with telomere length in breast cancer;Gene Reports;2020-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3